About: GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.84 (-8.16%)
GTBP NASDAQ GT Biopharma Inc
GT Biopharma Inc share price
Atividade de preço de GTBP
Último preço
$ 4,840
Variação (24h)
-0,43 USD (8,16%)
Volume
69.44K
Volume (média 4 sem.)
-
Abertura
$ 5,28
Variação do dia
$ 4,80 - $ 5,28
Fechamento anterior
$ 5,27
Último negócio
04 Nov, 9:00 pm GMT+0
Atrasado
04 Nov, 9:00 pm GMT+0
GTBP price performance
Atrasado
04 Nov, 9:00 pm GMT+0
GTBP details
quote.marketSignals